TAK, US8740602052

Takeda stock: TradingView reports USD 20.58 to USD 20.74 target rise for Takeda stock

Published on 10/20/2026 at 15:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-quarter revenue reached JPY 1.22 trillion, up 10.00 percent year over year. Takeda stock costs EUR 17.70 on October 20, 2026 at 3:00 p.m. CEST.

Target and quarterly figures

The average target rose from USD 20.58 to USD 20.74 on October 15, 2026.
First-quarter revenue reached JPY 1.22 trillion, up 10.00 percent year over year.
Takeda stock costs EUR 17.70 at Lang & Schwarz on October 20, 2026 at 3:00 p.m. CEST.
Second-quarter results are scheduled for October 29, 2026.

TAK, US8740602052, Illustration mit AI erstellt.

Takeda Pharmaceutical Company Limited's average 12-month analyst target rose from USD 20.58 to USD 20.74 in a report dated October 15, 2026, according to TradingView. The stock was trading at EUR 17.70 at Lang & Schwarz on October 20, 2026 at 3:00 p.m. CEST.

Revenue growth sets the tone

Takeda reported JPY 1.22 trillion in revenue for the first quarter of fiscal 2026, up 10.00 percent from the same period a year earlier. Net income was JPY 113.2 billion, down 8.90 percent year over year, according to Simply Wall St. The combination puts operating execution and product launches ahead of the next earnings release.

Stock position and valuation

Takeda's primary listing is on the Tokyo Stock Exchange, where the stock closed at JPY 6,310 on October 20, 2026. Its 52-week range was JPY 4,102 to JPY 6,315, while market capitalization stood at USD 62.4 billion on October 19, 2026. The Tokyo close was 1.06 percent above the prior close.

In the United States, Takeda traded under NYSE ticker TAK at USD 19.61 on October 19, 2026. The finance profile gives the company a price-to-earnings ratio of 56.25 and a dividend yield of 3.00 percent. These figures describe the home and U.S. listings separately from the euro quotation.

Which dates matter next?

Takeda is due to publish its second-quarter fiscal 2026 results on October 29, 2026, with an investor webcast scheduled for the same day, according to MarketScreener. Oncology data are also scheduled for presentation from October 23, 2026, at the European Society for Medical Oncology meeting.

What the target implies

The USD 20.74 average target is 5.77 percent above the USD 19.61 U.S. listing price on October 19, 2026. The calculation uses the same currency and keeps the analyst view distinct from the euro quotation. For investors, the next reported period will test whether revenue growth can offset the decline in net income.

Euro price stays in focus

Takeda's euro quotation was EUR 17.70 at Lang & Schwarz on October 20, 2026 at 3:00 p.m. CEST. Its Tokyo listing closed at JPY 6,310 on October 20, 2026, providing a separate home-market reference.

The further course of trading is shown by the continuously updated real-time quote of Takeda stock.